Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. - Wikidata - wikimedia - TriplyDB

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

http://www.wikidata.org/entity/Q40442570

about

Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells NRP1 function and targeting in neurovascular development and eye disease The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data.Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.Mast cell leukemia with prolonged survival on PKC412/midostaurin.Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.Recent advances in the understanding of mastocytosis: the role of KIT mutations.Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.An update on molecular genetics of gastrointestinal stromal tumours.KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.Lipid rafts are required for Kit survival and proliferation signals M-COPA suppresses endolysosomal Kit-Akt oncogenic signalling through inhibiting the secretory pathway in neoplastic mast cells.Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Current therapeutic strategies for acute myeloid leukaemia.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.New horizons in multiple myeloma therapy.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Future options for imatinib mesilate-resistant tumors.The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.Stat5 as a diagnostic marker for leukemia.YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia.Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.The role of mitogen- and stress-activated protein kinase pathways in melanoma.

P2860

Q24313261-24CDFDA8-8082-4307-B551-038897514C13 Q26765952-EA766D5F-ABFF-4953-9E1D-08F44818C913 Q27313466-B527F8EF-FFB0-4871-8311-66F7A4CFC322 Q27865182-790B1DE0-A3C5-4917-8794-176912941D85 Q28486691-C136ABA6-0F91-4780-B5DF-C7E7D8D8A087 Q28541374-60FA53F7-5EFB-4706-AE83-74C85F1B51D1 Q28828739-129247A1-0744-42C1-947A-7992DA8A4D4E Q31082982-C5CDCEBC-E9DC-4086-8EAD-51CF90AB27EC Q33631185-566BBCA1-E0EE-4D20-A27D-AAC139BF4262 Q33737479-C540C88D-E8AC-4FC1-ADF2-E6886CBB7FB4 Q33754603-BCF09A44-3034-4517-B068-577DD13EE2CF Q33898701-3D60F376-E138-4BAB-AA04-DF884472D301 Q34048276-2D302978-0012-4E5C-8677-BB33D954A0B5 Q34635424-D48C49A0-2A87-483D-BC57-C35C381D08E8 Q34833416-2B517160-9BCD-41CB-9AF8-1DC5B351433C Q34983846-5BCE50C4-0F53-44FC-9258-88649890B6B0 Q35051746-5D136315-6F4D-484D-9F43-7E94264F9AF0 Q35770066-A5B8135F-86C8-4E0F-A725-69CB55F93BEA Q35776437-76BE6944-BC94-46AB-B6E3-534C2007E026 Q35807869-E359DEB6-4548-40C3-AECE-7C2246DD9A86 Q35848377-D5B7ACD7-3958-44BA-9E0C-7DC3704E13A1 Q35990629-C799C0FA-6A32-48B0-8385-BB6875FCDCCD Q36344903-493FA3E4-0FEE-4346-BD97-11E61DB70F15 Q36381266-93B74A27-2AB2-4AD4-ADB4-BCAD0312A90A Q36406996-FD670163-DA34-4358-9980-74C2681A6B27 Q36539598-EB18522A-056D-427A-BD51-14B4154DFD44 Q36591388-1A9A6C3F-1217-4B44-A404-BF6F852BA3F8 Q36636660-70319F49-BF31-4249-A141-FF1FC7AC4AA9 Q36730397-4B9FF79B-8C5E-4365-9815-0F6FEDDF432F Q36964688-171EF125-B67F-44F1-8DD8-0AAD632EE44A Q36964732-3D90D689-CE34-4E09-BDCA-9DAF5B0B1312 Q37035281-3B90E85F-BB8A-4162-9F68-7593615C50DD Q37122693-D0082CCC-0B58-4619-9305-E80270DF28EA Q37144902-E720B8D3-8B6D-4BB7-AF68-30E205952954 Q37183513-508FF466-2C9C-4D65-9E11-53B6A2119454 Q37216023-0312DC9C-70D7-4F92-870D-B023904B34A6 Q37301320-D7267764-940A-4D10-8E64-CD20BAFFB2BE Q37379320-854E85E3-011C-450D-A0DE-26632D7881BF Q37462729-802BE2EE-02E7-4BD9-8E50-C053D6CEE108 Q37931402-71A0DAF8-E762-42D4-836D-05C849469A31

P2860

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

http://www.wikidata.org/entity/Q40442570

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Activation mutations of human ...... osine kinase inhibitor PKC412.

@en

type

label

Activation mutations of human ...... osine kinase inhibitor PKC412.

@en

prefLabel

Activation mutations of human ...... osine kinase inhibitor PKC412.

@en

P1433

Q40442570-3F4442E0-769C-43D2-A084-953AA31D0C36

P1476

Q40442570-B2712AA5-E5A9-4F35-B48B-35D2B436389C

P2093

Q40442570-190888F4-25F8-4A07-9EFF-F9F6A83221C5

Q40442570-63546109-AEC4-4D97-9BBE-217E8B6D4E49

Q40442570-68BB5432-E838-4108-8F63-47210A17C509

Q40442570-BE99950F-07D8-4290-BDBD-FD17B605D1B1

Q40442570-C6ACDBF0-4705-4B69-9697-553F249A43EA

Q40442570-C7317D01-396C-4BE7-A379-1E9A7AD72BD8

Q40442570-F282740A-78C4-4824-8BA0-7469AB8382CC

P2860

Q40442570-004838E5-4E03-43B3-9988-29A5310DEF43

Q40442570-0CD0AD08-4D44-4323-822A-DBD6CC6F125A

Q40442570-118118D4-B64A-474E-A7AC-857B0240D562

Q40442570-2E10327A-EADF-4956-B743-A686C16DC6C6

Q40442570-2EC3674C-ED0A-46D6-9777-A39F4490CF86

Q40442570-35B07A5F-8DEA-44C4-86FF-76322B41AF5B

Q40442570-3AE1B52F-187D-4E0E-957E-65D6C9510B8C

Q40442570-3E5E52C4-A82C-4B81-8587-4BAE0C96B4E1

Q40442570-4A8616F7-B996-41C4-A18F-A531010C3502

Q40442570-607A0924-8395-475B-B040-75840DB79A65

P304

Q40442570-4DD3493C-98DE-4772-92EB-DABD58C30ECC

P31

Q40442570-AB43141D-BC4A-4544-9E5C-297D9852F6D1

P356

Q40442570-E71E2B2A-E2B8-46AA-9B86-9681F356F812

P407

Q40442570-FFFE74FF-6E07-43D0-A8F3-D3062D3DF828

P433

Q40442570-33E03BB8-BB41-45B3-BA75-C1FCDF1BA3B5

P478

Q40442570-31F40572-8A38-4193-8516-E317264FFE75

P577

Q40442570-89EC1AE2-1E7A-4D41-885F-0D8220F66BA4

P5875

Q40442570-D61CEB6E-6EB4-4A1C-AB54-A644AAAF0CFB

P698

Q40442570-98A8E6C7-A5ED-45DD-812A-C81D7D645921

P932

Q40442570-2A904304-0159-445D-9B59-CC7F7FADA87B

P356

BLOOD-2004-12-4617

P1433

P1476

Activation mutations of human ...... osine kinase inhibitor PKC412.

@en

P2093

D Gary Gilliland

http://www.w3.org/2001/XMLSchema#string

Doriano Fabbro

http://www.w3.org/2001/XMLSchema#string

James D Griffin

http://www.w3.org/2001/XMLSchema#string

Jennifer Adelsperger

http://www.w3.org/2001/XMLSchema#string

Jennifer J Clark

http://www.w3.org/2001/XMLSchema#string

Joseph D Growney

http://www.w3.org/2001/XMLSchema#string

Richard Stone

http://www.w3.org/2001/XMLSchema#string

P2860

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Stem cell factor and hematopoiesis

Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Biology of gastrointestinal stromal tumors: KIT mutations and beyond.

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

P304

721-724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2004-12-4617

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7944717

http://www.w3.org/2001/XMLSchema#string

P698

15790786

http://www.w3.org/2001/XMLSchema#string

P932

1895184

http://www.w3.org/2001/XMLSchema#string